Journal of Clinical Endocrinology & Metabolism, Vol 81, 3289-3294, Copyright © 1996 by Endocrine Society

ARTICLES

Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease

MJ Seibel, HW Woitge, M Pecherstorfer, M Karmatschek, E Horn, H Ludwig, FP Armbruster and R Ziegler
Department of Medicine, University of Heidelberg, Germany. Markus_Seibel@krzmail.krz.uni-heidelberg.de

Bone sialoprotein (BSP) is a phosphorylated glycoprotein with a M(r) of 70-80 kDa that accounts for approximately 5-10% of the noncollagenous proteins of bone. Due to its relatively restricted distribution to mineralized tissues, BSP may serve as a potential marker of bone metabolism. Employing a recently developed RIA, serum BSP was measured in 133 healthy subjects, aged 20-80 yr, and in patients with primary hyperparathyroidism (pHPT; n = 26), Paget's disease of bone (PD; n = 14), untreated multiple myeloma (MM; n = 32), and breast cancer with bone metastases (BC; n = 19). Results were compared to clinical and laboratory data, including serum total alkaline phosphatase as a marker of bone formation, and the urinary cross-links pyridinoline (PYD) and deoxypyridinoline (DPD) as markers of bone resorption. In healthy adults, serum BSP values ranged between 5.0-21.6 ng/mL (5-95% interval), with a median of 10.5 ng/mL (total group). In healthy females, a linear correlation was found between serum BSP and age (r = 0.51; P < 0.001), with significantly higher values in postmenopausal than in premenopausal women (13.3 +/- 4.8 vs. 9.0 +/- 3.8; P < 0.01). In the healthy group, BSP values did not change with body mass index, lumbar bone mineral density, serum calcium, serum creatinine, or serum total alkaline phosphatase levels. In contrast, a weak, but significant, correlation was observed between serum BSP and the urinary excretion of PYD and DPD. Compared to those in healthy controls, serum BSP levels were significantly higher in patients with pHPT, PD, MM, or BC (P < 0.01 for all groups). These differences remained after analyses were adjusted for age and sex. In pHPT, serum BSP levels were closely correlated to urinary PYD and DPD (r = 0.87 and 0.83, respectively; P < 0.01), whereas in PD, no correlation was observed between any of the bone markers. Serum BSP levels were highest in patients with MM, and there was a significant difference between early and advanced stages of the disease (30.2 +/- 8.0 vs. 64.3 +/- 6.8; P < 0.01). In a subgroup of 15 patients with metastatic BC, iv bisphosphonate treatment resulted in a rapid reduction of serum BSP levels to 40% of the baseline values within 4 days of treatment. In conclusion, BSP appears to be a sensitive marker of bone turnover, and the present data suggest that its serum levels predominantly reflect processes related to bone resorption.

This article has been cited by other articles:

				P. Garnero New Biochemical Markers of Bone Turnover IBMS BoneKEy, March 1, 2008; 5(3): 84 - 102. [Abstract] [Full Text] [PDF]

				B. Fohr, C. R. Dunstan, and M. J. Seibel Markers of Bone Remodeling in Metastatic Bone Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075. [Abstract] [Full Text] [PDF]

				N. S. Fedarko, A. Jain, A. Karadag, M. R. Van Eman, and L. W. Fisher Elevated Serum Bone Sialoprotein and Osteopontin in Colon, Breast, Prostate, and Lung Cancer Clin. Cancer Res., December 1, 2001; 7(12): 4060 - 4066. [Abstract] [Full Text] [PDF]

				H. W. Woitge, E. Horn, A. V. Keck, B. Auler, M. J. Seibel, and M. Pecherstorfer Biochemical Markers of Bone Formation in Patients with Plasma Cell Dyscrasias and Benign Osteoporosis Clin. Chem., April 1, 2001; 47(4): 686 - 693. [Abstract] [Full Text] [PDF]

				H. W. Woitge, H. Oberwittler, S. Heichel, A. Grauer, R. Ziegler, and M. J. Seibel Short- and Long-Term Effects of Ibandronate Treatment on Bone Turnover in Paget Disease of Bone Clin. Chem., May 1, 2000; 46(5): 684 - 690. [Abstract] [Full Text] [PDF]

				I. J. Diel, E.-F. Solomayer, M. J. Seibel, J. Pfeilschifter, H. Maisenbacher, C. Gollan, M. Pecherstorfer, R. Conradi, G. Kehr, E. Boehm, et al. Serum Bone Sialoprotein in Patients with Primary Breast Cancer Is a Prognostic Marker for Subsequent Bone Metastasis Clin. Cancer Res., December 1, 1999; 5(12): 3914 - 3919. [Abstract] [Full Text] [PDF]

				B. Ganss, R.H. Kim, and J. Sodek Bone Sialoprotein Critical Reviews in Oral Biology & Medicine, January 1, 1999; 10(1): 79 - 98. [Abstract] [Full Text] [PDF]

				J.P. Gorski Is All Bone the Same? Distinctive Distributions and Properties of Non-Collagenous Matrix Proteins in Lamellar Vs. Woven Bone Imply the Existence of Different Underlying Osteogenic Mechanisms Critical Reviews in Oral Biology & Medicine, January 1, 1998; 9(2): 201 - 223. [Abstract] [Full Text] [PDF]

				M. Karmatschek, I. Maier, M. J. Seibel, H. W. Woitge, R. Ziegler, and F. P. Armbruster Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay Clin. Chem., November 1, 1997; 43(11): 2076 - 2082. [Abstract] [Full Text] [PDF]

				N. S. Fedarko, B. Fohr, P. G. Robey, M. F. Young, and L. W. Fisher Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack J. Biol. Chem., May 26, 2000; 275(22): 16666 - 16672. [Abstract] [Full Text] [PDF]